SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Holmberg Bjorn)
 

Sökning: WFRF:(Holmberg Bjorn) > Levodopa-carbidopa ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005765naa a2200553 4500
001oai:DiVA.org:liu-131707
003SwePub
008160930s2016 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:134148541
009oai:DiVA.org:uu-300787
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1317072 URI
0247 a https://doi.org/10.1016/j.parkreldis.2016.06.0022 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1341485412 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3007872 URI
040 a (SwePub)liud (SwePub)kid (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Pålhagen, Sven E.u Karolinska University Hospital, Sweden,Karolinska Univ Hosp, Dept Neurol, SE-14186 Stockholm, Sweden4 aut
2451 0a Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinsons disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs
264 1b ELSEVIER SCI LTD,c 2016
338 a electronic2 rdacarrier
500 a Funding Agencies|AbbVie Inc.
520 a Background: Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) can effectively manage motor and non-motor complications in advanced Parkinsons disease (PD). Healthcare costs, quality of life (QoL), effectiveness, and tolerability were assessed in routine care treatment with LCIG. Methods: The seventy-seven patients enrolled in this prospective, open-label, 3-year study in routine medical care were LCIG-naive (N = 37), or had previous LCIG treatment for amp;lt;2 (N = 22), or amp;gt;= 2 (N = 18) years. Healthcare costs were collected monthly. PD symptoms and QoL were assessed with the Unified Parkinsons Disease Rating Scale (UPDRS), 39-item Parkinsons Disease Questionnaire (PDQ-39), and EuroQoL 5-Dimension Visual Analog Scale (EQ-5D VAS); LCIG dose, safety, and tolerability were monitored. Results: Mean monthly costs per patient ( 8226 5952) were similar across cohorts, remained steady during 3-year follow-up, and increased with PD severity and QoL impairment. In LCIG-naive patients, significant improvements compared to baseline were observed on the UPDRS total score and PDQ-39 summary index score through 18 months (n = 24; UPDRS, p = 0.033; PDQ-39, p = 0.049). Symptom control was maintained during 3-year follow-up in LCIG-experienced cohorts. Small changes in mean daily LCIG dose were observed. Adverse events were common and generally related to the device, procedure, levodopa, or laboratory evaluations. Conclusions: Costs in LCIG-treated patients were stable over 3 years. LCIG treatment led to significant improvements in motor function and QoL over 18 months in LCIG-naive patients and no worsening was observed in LCIG-experienced patients over 3 years despite natural PD progression over time. The longterm safety was consistent with the established LCIG profile. (C) 2016 AbbVie Inc. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng
653 a Parkinsons disease; Levodopa; Infusion; LCIG; Cost
7001 a Sydow, Olofu Karolinska University Hospital, Sweden,Karolinska Univ Hosp, Dept Neurol, SE-14186 Stockholm, Sweden4 aut
7001 a Johansson, Andersu Uppsala universitet,Karolinska Institutet,Neurologi4 aut0 (Swepub:uu)andejoha
7001 a Nyholm, Dagu Uppsala universitet,Neurologi4 aut0 (Swepub:uu)danyh856
7001 a Holmberg, Bjornu Sahlgrens University Hospital, Sweden,Sahlgrens Univ Hosp, Dept Clin Neurosci, Gothenburg, Sweden4 aut
7001 a Widner, Hakanu Skåne University Hospital, Sweden,Skane Univ Hosp, Dept Neurol, Lund, Sweden4 aut
7001 a Dizdar Segrell, Nilu Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping,Linkoping Univ, Dept Neurol, Linkoping, Sweden; Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden4 aut0 (Swepub:liu)nildi39
7001 a Linder, Janu Norrlands University Hospital, Sweden,Norrlands Univ Hosp, Neuroctr, Dept Neurol, Umea, Sweden4 aut
7001 a Hauge, Toveu Molde Hospital HNR, Norway,Molde Hosp HNR, Dept Neurol, Molde, Norway4 aut
7001 a Jansson, Rasmusu Sundsvall Hospital, Sweden,Sundsvall Hosp, Dept Geriatr Med & Rehabil, Sundsvall, Sweden4 aut
7001 a Bergmann, Larsu AbbVie Inc, N Chicago, IL USA4 aut
7001 a Kjellander, Susannau AbbVie AB, Solna, Sweden4 aut
7001 a Marshall, Thomas S.u AbbVie Inc, N Chicago, IL USA4 aut
7102 a Karolinska University Hospital, Swedenb Karolinska Univ Hosp, Dept Neurol, SE-14186 Stockholm, Sweden4 org
7730 t Parkinsonism & Related Disordersd : ELSEVIER SCI LTDg 29, s. 17-23q 29<17-23x 1353-8020x 1873-5126
8564 u https://liu.diva-portal.org/smash/get/diva2:1010256/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u http://www.prd-journal.com/article/S1353802016301985/pdf
8564 u https://uu.diva-portal.org/smash/get/diva2:952448/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-131707
8564 8u https://doi.org/10.1016/j.parkreldis.2016.06.002
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:134148541
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-300787

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy